The effect of neuropeptide Y on cell survival and neurotrophin expression in in-vitro models of Alzheimer?s disease

Canadian Journal of Physiology and Pharmacology

Volumn 92, Issue 8, 2014, Pages 621-630

  Angelucci, Francesco ^a   Gelfo, Francesca ^b,c   Fiore, Marco ^a   Croce, Nicoletta ^a,b   Mathé, Aleksander A ^d   Bernardini, Sergio ^b   Caltagirone, Carlo ^b,c  

^a IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CNR   (Italy)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Amyloid ; Brain derived neurotrophic factor; In vitro models; Nerve growth factor; Neuropeptide Y; Neuroprotection; Neurotrophins

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM CHANNEL; NERVE GROWTH FACTOR; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL; CELL SURVIVAL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; TUMOR CELL LINE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM CHANNELS; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; NERVE GROWTH FACTORS; NEURONS; NEUROPEPTIDE Y; NEUROPROTECTIVE AGENTS;

EID: 84905011022     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/cjpp-2014-0099     Document Type: Review

References (135)

1. Agasse, F., Bernardino, L., Kristiansen, H., Christiansen, S.H., Ferreira, R., Silva, B., et al. 2008. Neuropeptide Y promotes neurogenesis in murine subventricular zone. Stem Cells, 26(6): 1636-1645. doi:10.1634/stemcells.2008- 0056. PMID:18388302
2. Allen, S.J., and Dawbarn, D. 2006. Clinical relevance of the neurotrophins and their receptors. Clin. Sci. (Lond.), 110(2): 175-191. doi:10.1042/CS20050161. PMID:16411894
3. Allen, S.J., MacGowan, S.H., Treanor, J.J., Feeney, R., Wilcock, G.K., and Dawbarn, D. 1991. Normal _-NGF content in Alzheimer's disease cerebral cortex and hippocampus. Neurosci. Lett., 131(1): 135-139. doi:10.1016/0304- 3940(91)90354-V. PMID:1791973
4. Allen, S.J., Watson, J.J., and Dawbarn, D. 2011. The neurotrophins and their role in Alzheimer's disease. Curr. Neuropharmacol. 9(4): 559-573. doi:10.2174/ 157015911798376190. PMID:22654716
5. Allen, Y.S., Adrian, T.E., Allen, J.M., Tatemoto, K., Crow, T.J., Bloom, S.R., et al. 1983. Neuropeptide Y distribution in the rat brain. Science, 221(4613): 877-879. doi:10.1126/science.6136091. PMID:6136091
6. Alom, J., Galard, R., Catalan, R., Castellanos, J.M., Schwartz, S., and Tolosa, E. 1990. Cerebrospinal fluid neuropeptide Y in Alzheimer's disease. Eur. Neurol. 30(4): 207-210. doi:10.1159/000117347. PMID:2209674
7. Alvaro, A.R., Martins, J., Costa, A.C., Fernandes, E., Carvalho, F., Ambrosio, A.F., et al. 2008. Neuropeptide Y protects retinal neural cells against cell death induced by Ecstasy. Neuroscience, 152(1): 97-105. doi:10.1016/j.neuroscience. 2007.12.027. PMID:18249070
8. Angelucci, F., Spalletta, G., di Iulio, F., Ciaramella, A., Salani, F., Colantoni, L., et al. 2010. Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients are characterized by increased BDNF serum levels. Curr. Alzheimer Res. 7(1): 15-20. doi:10.2174/156720510790274473. PMID:20205668
9. Angelucci, F., Gelfo, F., De Bartolo, P., Caltagirone, C., and Petrosini, L. 2011. BDNF concentrations are decreased in serum and parietal cortex in immunotoxin 192 IgG-Saporin rat model of cholinergic degeneration. Neurochem. Int. 59(1): 1-4. doi:10.1016/j.neuint.2011.04.010. PMID:21672569
10. Autry, A.E., and Monteggia, L.M. 2012. Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol. Rev. 64(2): 238-258. doi:10.1124/pr. 111.005108. PMID:22407616
11. Baptista, S., Bento, A.R., Goncalves, J., Bernardino, L., Summavielle, T., Lobo, A., et al. 2012. Neuropeptide Y promotes neurogenesis and protection against methamphetamine-induced toxicity in mouse dentate gyrus-derived neurosphere cultures. Neuropharmacology, 62(7): 2413-2423. doi:10.1016/j.neuro harm.2012.02.015. PMID:22381583
12. Barnea, A., Aguila-Mansilla, N., Chute, H.T., and Welcher, A.A. 1996. Comparison of neurotrophin regulation of human and rat neuropeptide Y (NPY) neurons: induction of NPY production in aggregate cultures derived from rat but not from human fetal brains. Brain Res. 732(1-2): 52-60. doi:10.1016/0006- 8993(96)00486-6. PMID:8891268
13. Beal, M.F., Mazurek, M.F., Chattha, G.K., Svendsen, C.N., Bird, E.D., and Martin, J.B. 1986. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann. Neurol. 20(3): 282-288. doi:10.1002/ana. 410200303. PMID:3767313
14. Beattie, M.S., Harrington, A.W., Lee, R., Kim, J.Y., Boyce, S.L., Longo, F.M., et al. 2002. ProNGF induces p75-mediated death of oligodendrocytes following spinal cord injury. Neuron, 36(3): 375-386. doi:10.1016/S0896-6273(02)01005-X. PMID:12408842
15. Beck, B. 2006. Neuropeptide Y in normal eating and in genetic and dietaryinduced obesity. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361(1471): 1159-1185. doi:10.1098/rstb.2006.1855. PMID:16874931
16. Binder, D.K. 2004. The role of BDNF in epilepsy and other diseases of the mature nervous system. Adv. Exp. Med. Biol. 548: 34-56. doi:10.1007/978-1-4757-6376- 8_3. PMID:15250584
17. Bjornebekk, A., Mathe, A.A., and Brene, S. 2010. The antidepressant effects of running and escitalopram are associated with levels of hippocampal NPY and Y1 receptor but not cell proliferation in a rat model of depression. Hippocampus, 20(7): 820-828. doi:10.1002/hipo.20683. PMID:19623606
18. Blennow, K., de Leon, M.J., and Zetterberg, H. 2006. Alzheimer's disease. Lancet, 368(9533): 387-403. doi:10.1016/S0140-6736(06)69113-7. PMID:16876668
19. Cavallucci, V., D'Amelio, M., and Cecconi, F. 2012. A_ toxicity in Alzheimer's disease. Mol. Neurobiol. 45(2): 366-378. doi:10.1007/s12035-012-8251-3. PMID: 22415442
20. Chan-Palay, V., Lang, W., Allen, Y.S., Haesler, U., and Polak, J.M. 1985. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia. J. Comp. Neurol. 238(4): 390-400. doi:10.1002/cne.902380404. PMID:2413088
21. Chan-Palay, V., Lang, W., Haesler, U., Kohler, C., and Yasargil, G. 1986. Distribution of altered hippocampal neurons and axons immunoreactive with antisera against neuropeptide Y in Alzheimer's-type dementia. J. Comp. Neurol. 248(3): 376-394. doi:10.1002/cne.902480307. PMID:3522663
22. Chao, M.V. 2003. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat. Rev. Neurosci. 4(4): 299-309. doi:10.1038/ nrn1078. PMID:12671646
23. Choi, D.W. 1985. Glutamate neurotoxicity in cortical cell culture is calcium dependent. Neurosci. Lett. 58(3): 293-297. doi:10.1016/0304-3940(85)90069-2.PMID:2413399
24. Cohen, H., Liu, T., Kozlovsky, N., Kaplan, Z., Zohar, J., and Mathe, A.A. 2012. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology, 37(2): 350-363. doi:10.1038/npp.2011.230. PMID: 21976046
25. Colmers, W.F., and Bleakman, D. 1994. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 17(9): 373-379. doi:10.1016/0166- 2236(94)90046-9. PMID:7529442
26. Connor, B., Young, D., Yan, Q., Faull, R.L., Synek, B., and Dragunow, M. 1997. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res. Mol. Brain Res. 9(1-2): 71-81. doi:10.1016/S0169-328X(97)00125-3. PMID: 1850079
27. Cooper, J.D., Salehi, A., Delcroix, J.D., Howe, C.L., Belichenko, P.V., Chua-Couzens, J., et al. 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U.S.A. 98(18): 10439-10444. doi:10.1073/pnas.181219298. PMID:11504920
28. Corvino, V., Marchese, E., Giannetti, S., Lattanzi, W., Bonvissuto, D., Biamonte, F., et al. 2012. The neuroprotective and neurogenic effects of neuropeptide Y administration in an animal model of hippocampal neurodegeneration and temporal lobe epilepsy induced by trimethyltin. J. Neurochem. 122(2): 415-426. doi:10.1111/j.1471-4159.2012.07770.x. PMID:22537092
29. Counts, S.E., and Mufson, E.J. 2005. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J. Neuropathol. Exp. Neurol. 64(4): 263-272. PMID:15835262
30. Croce, N., Dinallo, V., Ricci, V., Federici, G., Caltagirone, C., Bernardini, S., et al. 2011. Neuroprotective effect of neuropeptide Y against _-amyloid 25-35 toxicity in SH-SY5Y neuroblastoma cells is associated with increased neurotrophin production. Neurodegener. Dis. 8(5): 300-309. doi:10.1159/000323468.PMID:21346312
31. Croce, N., Ciotti, M.T., Gelfo, F., Cortelli, S., Federici, G., Caltagirone, C., et al. 2012. Neuropeptide Y protects rat cortical neurons against -amyloid toxicity and re-establishes synthesis and release of nerve growth factor. ACS Chem. Neurosci. 3(4): 312-318. doi:10.1021/cn200127e. PMID:22860197
32. Croce, N., Gelfo, F., Ciotti, M.T., Federici, G., Caltagirone, C., Bernardini, S., et al. 2013. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model of Alzheimer disease: a possible role in neuroprotection? Mol. Cell Biochem., 376(1-2): 189-195. doi:10.1007/s11010-013-1567-0. PMID: 23358924
33. Cuello, A.C., Bruno, M.A., Allard, S., Leon, W., and Iulita, M.F. 2010. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J. Mol. Neurosci. 40(1-2): 230-235. doi:10.1007/s12031-009-9238-z. PMID:19680822
34. Davies, C.A., Morroll, D.R., Prinja, D., Mann, D.M., and Gibbs, A. 1990. A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J. Neurol. Sci. 96(1): 59-73. doi:10.1016/0022-510X(90)90057-T. PMID: 1972185
35. Decressac, M., and Barker, R.A. 2012. Neuropeptide Y and its role in CNS disease and repair. Exp. Neurol. 238(2): 265-272. doi:10.1016/j.expneurol.2012.09.004. PMID:23022456
36. Decressac, M., Wright, B., Tyers, P., Gaillard, A., and Barker, R.A. 2010. Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease. Exp. Neurol. 226(1): 24-32. doi:10.1016/j.expneurol.2010.07. 022. PMID:20673761
37. Decressac, M., Pain, S., Chabeauti, P.Y., Frangeul, L., Thiriet, N., Herzog, H., et al. 2012. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging, 33(9): 2125-2137. doi:10.1016/j.neuro biolaging.2011.06.018. PMID:21816512
38. Domin, H., Kajta, M., and Smiałowska, M. 2006. Neuroprotective effects of MTEP, a selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in primary neuronal cultures. Pharmacol. Rep. 58(6): 846-858. PMID: 17220542
39. dos Santos, V.V., Santos, D.B., Lach, G., Rodrigues, A.L., Farina, M., De Lima, T.C., et al. 2013. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid- (A(1-40)) administration in mice. Behav. Brain Res. 244: 107-115. doi:10.1016/j.bbr.2013.01.039. PMID:23396168
40. Dumont, Y., Jacques, D., Bouchard, P., and Quirion, R. 1998. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J. Comp. Neurol. 402(3): 372-384. doi:10.1002/(SICI)1096-9861(19981221)402:3%3C372::AID-CNE6% 3E3.0.CO;2-2. PMID:9853905
41. Dyzma, M., Boudjeltia, K.Z., Faraut, B., and Kerkhofs, M. 2010. Neuropeptide Y and sleep. Sleep Med. Rev. 14(3): 161-165. doi:10.1016/j.smrv.2009.09.001. PMID:20122859
42. Eacker, S.M., Dawson, T.M., and Dawson, V.L. 2013. The interplay of microRNA and neuronal activity in health and disease. Front. Cell. Neurosci. 7: 136. doi:10.3389/fncel.2013.00136. PMID:23986658
43. Edvinsson, L., Minthon, L., Ekman, R., and Gustafson, L. 1993. Neuropeptides in cerebrospinal fluid of patients with Alzheimer's disease and dementia with frontotemporal lobe degeneration. Dementia, 4(3-4): 167-171. doi:10.1159/ 000107318. PMID:8401787
44. El Bahh, B., Auvergne, R., Lere, C., Brana, C., Le Gal La Salle, G., and Rougier, A. 2001. Decreased epileptic susceptibility correlates with neuropeptide Y overexpression in a model of tolerance to excitotoxicity. Brain Res. 894(2): 209-217. doi:10.1016/S0006-8993(01)02027-3. PMID:11251194
45. El Bahh, B., Balosso, S., Hamilton, T., Herzog, H., Beck-Sickinger, A.G., Sperk, G., et al. 2005. The anti-epileptic actions of neuropeptide Y in the hippocampus are mediated by Y2 and not Y5 receptors. Eur. J. Neurosci. 22(6): 1417-1430. doi:10.1111/j.1460-9568.2005.04338.x. PMID:16190896
46. Eriksdotter, J.M., Nordberg, A., Amberla, K., Backman, L., Ebendal, T., Meyerson, B., et al. 1998. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 9(5): 246-257. doi:10.1159/000017069. PMID:9701676
47. Fahnestock, M., Michalski, B., Xu, B., and Coughlin, M.D. 2001. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol. Cell. Neurosci. 18(2): 210-220. doi:10.1006/mcne.2001.1016. PMID:11520181
48. Fahnestock, M., Garzon, D., Holsinger, R.M., and Michalski, B. 2002. Neurotrophic factors and Alzheimer's disease: are we focusing on the wrong molecule? J. Neural Transm. Suppl. (62): 241-252. doi:10.1007/978-3-7091-6139- 5_22. MID:12456067
49. Forlenza, O.V., Diniz, B.S., Teixeira, A.L., Ojopi, E.B., Talib, L.L., Mendonca, V.A., et al. 2010. Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J. Biol. Psychiatry, 11(6): 774-780. doi:10.3109/15622971003797241. PMID:20491609
50. Fumagalli, F., Molteni, R., Calabrese, F., Maj, P.F., Racagni, G., and Riva, M.A. 2008. Neurotrophic factors in neurodegenerative disorders: potential for therapy. CNS Drugs, 22(12): 1005-1019. doi:10.2165/0023210-200822120-00004. PMID:18998739
51. Garza-Manero, S., Pichardo-Casas, I., Arias, C., Vaca, L., and Zepeda, A. 2013. Selective distribution and dynamic modulation of miRNAs in the synapse and its possible role in Alzheimer's Disease. Brain Res. S0006-8993(13): 01536-01539. doi:10.1016/j.brainres.2013.12.009. PMID:24355599
52. Gelfo, F., De Bartolo, P., Tirassa, P., Croce, N., Caltagirone, C., Petrosini, L., et al. 2011a. Intraperitoneal injection of neuropeptide Y (NPY) alters neurotrophin rat hypothalamic levels: Implications for NPY potential role in stress-related disorders. Peptides, 32(6): 1320-1323. doi:10.1016/j.peptides.2011.03.023. PMID: 21473895
53. Gelfo, F., Tirassa, P., De Bartolo, P., Caltagirone, C., Petrosini, L., and Angelucci, F. 2011b. Brain and serum levels of nerve growth factor in a rat model of Alzheimer's disease. J. Alzheimers Dis. 25(2): 213-217. doi:10.3233/ JAD-2011-110047. PMID:21368378
54. Gelfo, F., Tirassa, P., De Bartolo, P., Croce, N., Bernardini, S., Caltagirone, C., et al. 2012. NPY intraperitoneal injections produce antidepressant-like effects and downregulate BDNF in the rat hypothalamus. CNS Neurosci. Ther. 18(6): 487-492. doi:10.1111/j.1755-5949.2012.00314.x. PMID:22672302
55. Gericke, C.A., Lang, U.E., Steckler, T., Schulze, G., Bajbouj, M., and Hellweg, R. 2003. Nerve growth factor response to excitotoxic lesion of the cholinergic basal forebrain is slightly impaired in aged rats. J. Neural Transm. 110(6): 627-639. doi:10.1007/s00702-002-0819-z. PMID:12768358
56. Goyal, S.N., Upadhya, M.A., Kokare, D.M., Bhisikar, S.M., and Subhedar, N.K. 2009. Neuropeptide Y modulates the antidepressant activity of imipramine in olfactory bulbectomized rats: involvement of NPY Y1 receptors. Brain Res. 1266: 45-53. doi:10.1016/j.brainres.2009.02.033. PMID:19254701
57. Greber, S., Schwarzer, C., and Sperk, G. 1994. Neuropeptide Y inhibits potassiumstimulated glutamate release through Y2 receptors in rat hippocampal slices in vitro. Br. J. Pharmacol. 113(3): 737-740. doi:10.1111/j.1476-5381.1994.tb17055.x. PMID:7858862
58. Greer, P.L., and Greenberg, M.E. 2008. From synapse to nucleus: calciumdependent gene transcription in the control of synapse development and function. Neuron, 59(6): 846-860. doi:10.1016/j.neuron.2008.09.002. PMID: 18817726
59. Gutman, A.R., Yang, Y., Ressler, K.J., and Davis, M. 2008. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci. 28(48): 12682-12690. doi:10.1523/JNEUROSCI.2305-08.2008. PMID:19036961
60. Harrington, A.W., Leiner, B., Blechschmitt, C., Arevalo, J.C., Lee, R., Morl, K., et al. 2004. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc. Natl. Acad. Sci. U.S.A. 101(16): 6226-6230. doi:10.1073/pnas.0305755101. PMID:15026568
61. Hellweg, R., Humpel, C., Lowe, A., and Hortnagl, H. 1997. Moderate lesion of the rat cholinergic septohippocampal pathway increases hippocampal nerve growth factor synthesis: evidence for long-term compensatory changes? Brain Res. Mol. Brain Res. 45(1): 177-181. doi:10.1016/S0169-328X(96)00310-5. PMID:9105689
62. Hellweg, R., Gericke, C.A., Jendroska, K., Hartung, H.D., and Cervos-Navarro, J. 1998. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int. J. Dev. Neurosci. 16(7-8): 787-794. doi:10.1016/S0736-5748(98)00088-4. PMID:10198825
63. Hellweg, R., Lohmann, P., Huber, R., Kuhl, A., and Riepe, M.W. 2006. Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment. Learn. Mem. 13(1): 63-71. doi:10.1101/lm.2606. PMID:16418433
64. Hock, C., Heese, K., Hulette, C., Rosenberg, C., and Otten, U. 2000. Regionspecific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch. Neurol. 57(6): 846-851. doi:10. 1001/archneur.57.6.846. PMID:10867782
65. Holtzman, D.M., Morris, J.C., and Goate, A.M. 2011. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 3(77): 77sr1. doi:10.1126/ scitranslmed.3002369. PMID:21471435
66. Howell, O.W., Doyle, K., Goodman, J.H., Scharfman, H.E., Herzog, H., Pringle, A., et al. 2005. Neuropeptide Y stimulates neuronal precursor proliferation in the post-natal and adult dentate gyrus. J. Neurochem. 93(3): 560-570. doi:10. 1111/j.1471-4159.2005.03057.x. PMID:15836615
67. Howell, O.W., Silva, S., Scharfman, H.E., Sosunov, A.A., Zaben, M., Shatya, A., et al. 2007. Neuropeptide Y is important for basal and seizure-induced precursor cell proliferation in the hippocampus. Neurobiol. Dis. 26(1): 174-188. doi:10.1016/j.nbd.2006.12.014. PMID:17317195
68. Huang, E.J., and Reichardt, L.F. 2001. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24: 677-736. doi:10.1146/annurev. neuro.24.1.677. PMID:11520916
69. Huang, Y., and Mucke, L. 2012. Alzheimer mechanisms and therapeutic strategies. Cell, 148(6): 1204-1222. doi:10.1016/j.cell.2012.02.040. PMID:22424230
70. Jimenez-Mateos, E.M., Mouri, G., Conroy, R.M., and Henshall, D.C. 2010. Epileptic tolerance is associated with enduring neuroprotection and uncoupling of the relationship between CA3 damage, neuropeptide Y rearrangement and spontaneous seizures following intra-amygdala kainic acid-induced status epilepticus in mice. Neuroscience, 171(2): 556-565. doi:10.1016/j.neuroscience.2010. 09.003. PMID:20837105
71. Jimenez-Vasquez, P.A., Diaz-Cabiale, Z., Caberlotto, L., Bellido, I., Overstreet, D., Fuxe, K., et al. 2007. Electroconvulsive stimuli selectively affect behavior and neuropeptide Y (NPY) and NPY Y(1) receptor gene expressions in hippocampus and hypothalamus of Flinders Sensitive Line rat model of depression. Eur.Neuropsychopharmacol.17(4):298-308. doi:10.1016/j.euroneuro.2006.06. 011. PMID:16904299
72. Koide, S., Onishi, H., Hashimoto, H., Kai, T., and Yamagami, S. 1995. Plasma neuropeptide Y is reduced in patients with Alzheimer's disease. Neurosci. Lett. 198(2): 149-151. doi:10.1016/0304-3940(95)11973-Z. PMID:8592643
73. Kowall, N.W., and Beal, M.F. 1988. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: normal anatomy and alterations in Alzheimer's disease. Ann. Neurol. 23(2): 105-114. doi:10.1002/ana.410230202. PMID:2897822
74. Kozisek, M.E., Middlemas, D., and Bylund, D.B. 2008. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol. Ther. 117(1): 30-51. doi:10.1016/ j.pharmthera.2007.07.001. PMID:17949819
75. Laske, C., Stransky, E., Leyhe, T., Eschweiler, G.W., Wittorf, A., Richartz, E., et al. 2006. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J. Neural Transm. 113(9): 1217-1224. doi:10.1007/s00702-005-0397-y. PMID: 16362629
76. Laske, C., Stransky, E., Leyhe, T., Eschweiler, G.W., Maetzler, W., Wittorf, A., et al. 2007. BDNF serum and CSF concentrations in Alzheimer's disease, normal pressure hydrocephalus and healthy controls. J. Psychiatr. Res. 41(5): 387-394. doi:10.1016/j.jpsychires.2006.01.014. PMID:16554070
77. Liu, H., Liu, Z., Xu, X., Yang, X., Wang, H., and Li, Z. 2010. Nerve growth factor regulates galanin and neuropeptide Y expression in primary cultured superior cervical ganglion neurons. Pharmazie, 65(3): 219-223. doi:10.1691/ph. 2010.9558. PMID:20383944
78. Lu, B., Pang, P.T., and Woo, N.H. 2005. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 6(8): 603-614. doi:10.1038/nrn1726. PMID:16062169
79. Malva, J.O., Xapelli, S., Baptista, S., Valero, J., Agasse, F., Ferreira, R., et al. 2012. Multifaces of neuropeptide Y in the brain -neuroprotection, neurogenesis and neuroinflammation. Neuropeptides, 46(6): 299-308. doi:10.1016/j.npep. 2012.09.001. PMID:23116540
80. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. 2010. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 9(7): 702-716. doi:10.1016/S1474-4422(10)70119-8. PMID:20610346
81. Martel, J.C., Alagar, R., Robitaille, Y., and Quirion, R. 1990. Neuropeptide Y receptor binding sites in human brain. Possible alteration in Alzheimer's disease. Brain Res. 519(1-2): 228-235. doi:10.1016/0006-8993(90)90082-M. PMID:2168782
82. Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. 1992. Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 4(3): 191-205. doi:10.1007/BF02260903. PMID:1320891
83. Mattson, M.P., Rydel, R.E., Lieberburg, I., and Smith-Swintosky, V.L. 1993. Altered calcium signaling and neuronal injury: stroke and Alzheimer's disease as examples. Ann. N.Y. Acad. Sci. 679: 1-21. doi:10.1111/j.1749-6632.1993.tb18285.x. PMID:8512177
84. Mellios, N., Huang, H.S., Grigorenko, A., Rogaev, E., and Akbarian, S. 2008. A set of differentially expressed miRNAs, including miR-30a-5p, act as posttranscriptional inhibitors of BDNF in prefrontal cortex. Hum. Mol. Genet. 17(19): 3030-3042. doi:10.1093/hmg/ddn201. PMID:18632683
85. Michalski, B., and Fahnestock, M. 2003. Pro-brainderived neurotrophic factor is decreased in parietal cortex in Alzheimer's disease. Brain Res. Mol. Brain Res. 111(1-2): 148-154. doi:10.1016/S0169-328X(03)00003-2. PMID:12654514
86. Michel, M.C., Beck-Sickinger, A., Cox, H., Doods, H.N., Herzog, H., Larhammar, D., et al. 1998. XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50(1): 143-150. PMID:9549761
87. Minthon, L., Edvinsson, L., Ekman, R., and Gustafson, L. 1990. Neuropeptide levels in Alzheimer's disease and dementia with frontotemporal degeneration. J. Neural Transm. Suppl. 30: 57-67. doi:10.1007/978-3-7091-3345-3_6. PMID:1975266
88. Minthon, L., Edvinsson, L., and Gustafson, L. 1996. Correlation between clinical characteristics and cerebrospinal fluid neuropeptide Y levels in dementia of the Alzheimer type and frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 10(4): 197-203. doi:10.1097/00002093-199601040-00005. PMID:8939279
89. Mufson, E.J., Kroin, J.S., Sendera, T.J., and Sobreviela, T. 1999. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 57(4): 451-484. doi:10.1016/S0301-0082(98)00059-8. PMID:10080385
90. Nagahara, A.H., Merrill, D.A., Coppola, G., Tsukada, S., Schroeder, B.E., Shaked, G.M., et al. 2009. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat. Med. 15(3): 331-337. doi:10.1038/nm.1912. PMID:19198615
91. Niewiadomska, G., Mietelska-Porowska, A., and Mazurkiewicz, M. 2011. The cholinergic system, nerve growth factor and the cytoskeleton. Behav. Brain Res. 221(2): 515-526. doi:10.1016/j.bbr.2010.02.024. PMID:20170684
92. Numakawa, T., Richards, M., Adachi, N., Kishi, S., Kunugi, H., and Hashido, K. 2011. MicroRNA function and neurotrophin BDNF. Neurochem. Int. 59(5): 551-558. doi:10.1016/j.neuint.2011.06.009. PMID:21723895
93. Nykjaer, A., Willnow, T.E., and Petersen, C.M. 2005. p75NTR: live or let die. Curr. Opin. Neurobiol. 15(1): 49-57. doi:10.1016/j.conb.2005.01.004. PMID:15721744
94. Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., et al. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron, 55(5): 697-711. doi:10.1016/j.neuron.2007.07.025. PMID:17785178
95. Park, H., and Poo, M.M. 2013. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 14(1): 7-23. doi:10.1038/nrc3653. PMID:23254191
96. Parks, J.K., Smith, T.S., Trimmer, P.A., Bennett, J.P., Jr., and Parker, W.D., Jr. 2001. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDAreceptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J. Neurochem. 76(4): 1050-1056. doi:10.1046/j.1471-4159.2001.00112.x. PMID: 11181824
97. Peng, S., Wuu, J., Mufson, E.J., and Fahnestock, M. 2005. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J. Neurochem. 93(6): 1412-1421. doi:10.1111/j.1471-4159.2005.03135.x. PMID: 15935057
98. Peng, S., Garzon, D.J., Marchese, M., Klein, W., Ginsberg, S.D., Francis, B.M., et al. 2009. Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease. J. Neurosci. 29(29): 9321-9329. doi:10.1523/JNEUROSCI.4736-08.2009. PMID:19625522
99. Phillips, H.S, Hains, J.M., Armanini, M., Laramee, G.R., Johnson, S.A., and Winslow, J.W. 1991. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron, 7(5): 695-702. doi:10.1016/0896- 6273(91)90273-3. PMID:1742020
100. Qian, J., Colmers, W.F., and Saggau, P. 1997. Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J. Neurosci. 17(21): 8169-8177. PMID:9334392
101. Querfurth, H.W., and LaFerla, F.M. 2010. Alzheimer's disease. N. Engl. J. Med. 362(4): 329-344. doi:10.1056/NEJMra0909142. PMID:20107219
102. Ramos, B., Baglietto-Vargas, D., del Rio, J.C., Moreno-Gonzalez, I., Santa-Maria, C., Jimenez, S., et al. 2006. Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol. Aging, 27(11): 1658-1672. doi:10.1016/j.neurobiolaging. 2005.09.022. PMID:16271420
103. Redrobe, J.P., Dumont, Y., St-Pierre, J.A., and Quirion, R. 1999. Multiple receptors for neuropeptide Y in the hippocampus: putative roles in seizures and cognition. Brain Res. 848(1-2): 153-166. doi:10.1016/S0006-8993(99)02119-8. PMID: 10612707
104. Rege, S.D., Geetha, T., Pondugula, S.R., Zizza, C.A., Wernette, C.M., and Babu, J.R. 2013. Noncoding RNAs in neurodegenerative diseases. ISRN Neurol. 2013: 375852. doi:10.1155/2013/375852. PMID:23738143
105. Reichardt, L.F. 2006. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361(1473): 1545-1564. doi:10.1098/rstb.2006.1894. PMID:16939974
106. Reitz, C., Brayne, C., and Mayeux, R. 2011. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7(3): 137-152. doi:10.1038/nrneurol.2011.2. PMID:21304480
107. Rose, J.B., Crews, L., Rockenstein, E., Adame, A., Mante, M., Hersh, L.B., et al. 2009. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J. Neurosci. 29(4): 1115-1125. doi:10.1523/JNEUROSCI.4220-08.2009. PMID:19176820
108. Rossner, S., Wortwein, G., Gu, Z., Yu, J., Schliebs, R., Bigl, V., et al. 1997. Cholinergic control of nerve growth factor in adult rats: evidence from cortical cholinergic deafferentation and chronic drug treatment. J. Neurochem. 69(3): 947-953. PMID:9282916
109. Salehi, A., Delcroix, J.D., and Swaab, D.F. 2004. Alzheimer's disease and NGF signaling. J. Neural. Transm. 111(3): 323-345. doi:10.1007/s00702-003-0091-x. PMID:14991458
110. Schaub, R.T., Anders, D., Golz, G., Gohringer, K., and Hellweg, R. 2002. Serum nerve growth factor concentration and its role in the preclinical stage of dementia. Am. J. Psychiatry, 159(7): 1227-1229. doi:10.1176/appi.ajp.159.7. 1227. PMID:12091204
111. Schliebs, R., and Arendt, T. 2011. The cholinergic system in aging and neuronal degeneration. Behav. Brain Res. 221(2): 555-563. doi:10.1016/j.bbr.2010.11.058. PMID:21145918
112. Schulte-Herbruggen, O., Eckart, S., Deicke, U., Kuhl, A., Otten, U., Danker-Hopfe, H., et al. 2008. Age-dependent time course of cerebral brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 in APP23 transgenic mice. J. Neurosci. Res. 86(12): 2774-2783. doi:10.1002/jnr.21704. PMID: 18438945
113. Selkoe, D.J. 2000. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann. N.Y. Acad. Sci. 924: 17-25. doi:10. 1111/j.1749-6632.2000.tb05554.x. PMID:11193794
114. Shaughnessy, L.W., and Barone, S., Jr. 1997. Damage to the NBM leads to a sustained lesion-induced increase in functional NGF in the cortex. Neuroreport, 8(12): 2767-2774. doi:10.1097/00001756-199708180-00024. PMID:9295115
115. Silva, A.P., Carvalho, A.P., Carvalho, C.M., and Malva, J.O. 2001. Modulation of intracellular calcium changes and glutamate release by neuropeptide Y1 and Y2 receptors in the rat hippocampus: differential effects in CA1, CA3 and dentate gyrus. J. Neurochem. 79(2): 286-296. doi:10.1046/j.1471-4159.2001. 00560.x. PMID:11677256
116. Silva, A.P., Pinheiro, P.S., Carvalho, A.P., Carvalho, C.M., Jakobsen, B., Zimmer, J., et al. 2003a. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 17(9): 1118-1120. doi:10.1096/fj.02-0885fje. PMID:12692082
117. Silva, A.P., Carvalho, A.P., Carvalho, C.M., and Malva, J.O. 2003b. Functional interaction between neuropeptide Y receptors and modulation of calcium channels in the rat hippocampus. Neuropharmacology, 44(2): 282-292. doi: 10.1016/S0028-3908(02)00382-9. PMID:12623227
118. Silva, A.P., Xapelli, S., Grouzmann, E., and Cavadas, C. 2005. The putative neuroprotective role of neuropeptide Y in the central nervous system. Curr. Drug Targets CNS Neurol. Disord. 4(4): 331-347. doi:10.2174/1568007054546153. PMID:16101553
119. Smiałowska, M., Wierońska, J.M., and Szewczyk, B. 2003. Neuroprotective effect of NPY on kainate neurotoxicity in the hippocampus. Pol. J. Pharmacol. 55(6): 979-986.PMID:14730092
120. Smiałowska, M., Domin, H., Zieba, B., Koź niewska, E., Michalik, R., Piotrowski, P., et al. 2009. Neuroprotective effects of neuropeptide Y-Y2 and Y5 receptor agonists in vitro and in vivo. Neuropeptides, 43(3): 235-249. doi:10.1016/j.npep.2009.02.002. PMID:19318226
121. Stanic, D., Paratcha, G., Ledda, F., Herzog, H., Kopin, A.S., and Hokfelt, T. 2008. Peptidergic influences on proliferation, migration, and placement of neural progenitors in the adult mouse forebrain. Proc. Natl. Acad. Sci. U.S.A. 105(9): 3610-3615. doi:10.1073/pnas.0712303105. PMID:18305161
122. Tao, X., West, A.E., Chen, W.G., Corfas, G., and Greenberg, M.E. 2002. A calciumresponsive transcription factor, CaRF, that regulates neuronal activitydependent expression of BDNF. Neuron, 33(3): 383-395. doi:10.1016/S0896-6273 (01)00561-X. PMID:11832226
123. Tatemoto, K. 1982. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc. Natl. Acad. Sci. U.S.A. 79(18): 5485-5489. doi:10.1073/pnas.79. 18.5485. PMID:6957876
124. Tatemoto, K., Carlquist, M., and Mutt, V. 1982. Neuropeptide Y- a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature, 296(5858): 659-660. doi:10.1038/296659a0. PMID:6896083
125. Thies, W., Bleiler, L., and Alzheimer's Association. 2013. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 9(2): 208-245. doi:10.1016/j.jalz.2013. 02.003. PMID:23507120
126. Thiriet, N., Deng, X., Solinas, M., Ladenheim, B., Curtis, W., Goldberg, S.R., et al. 2005. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J. Neurosci. 25(22): 5273-5279. doi:10.1523/ NEUROSCI.4893-04.2005. PMID:15930374
127. Tuszynski, M.H. 2007. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 21(2): 179-189. doi:10.1097/WAD. 0b013e318068d6d2. PMID:17545746
128. van den Pol, A.N. 2012. Neuropeptide transmission in brain circuits. Neuron, 76(1): 98-115. doi:10.1016/j.neuron.2012.09.014. PMID:23040809
129. Walker, P., Grouzmann, E., Burnier, M., and Waeber, B. 1991. The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol. Sci. 12(3): 111-115. doi:10.1016/0165-6147(91)90518-W. PMID:2053188
130. Wilcock, D.M., Lewis, M.R., Van Nostrand, W.E., Davis, J., Previti, M.L., Gharkholonarehe, N., et al. 2008. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 28(7): 1537-1545. doi:10.1523/JNEUROSCI.5066-07.2008. PMID:18272675
131. Wu, Y.F., and Li, S.B. 2005. Neuropeptide Y expression in mouse hippocampus and its role in neuronal excitotoxicity. Acta Pharmacol. Sin. 26(1): 63-68. doi:10.1111/j.1745-7254.2005.00011.x. PMID:15659116
132. Wu, G., Feder, A., Wegener, G., Bailey, C., Saxena, S., Charney, D., et al. 2011. Central functions of neuropeptide Y in mood and anxiety disorders. Expert Opin. Ther. Targets, 15(11): 1317-1331. doi:10.1517/14728222.2011.628314. PMID: 21995655
133. Xapelli, S., Silva, A.P., Ferreira, R., and Malva, J.O. 2007. Neuropeptide Y can rescue neurons from cell death following the application of an excitotoxic insult with kainite in rat organotypic hippocampal slice cultures. Peptides, 28(2): 288-294. doi:10.1016/j.peptides.2006.09.031. PMID:17212973
134. Xapelli, S., Bernardino, L., Ferreira, R., Grade, S., Silva, A.P., Salgado, J.R., et al. 2008. Interaction between neuropeptide Y (NPY) and brain-derived neurotrophic factor in NPY-mediated neuroprotection against excitotoxicity: a role for microglia. Eur. J. Neurosci. 27(8): 2089-2102. doi:10.1111/j.1460-9568. 2008.06172.x. PMID:18412629
135. Zheng, F., Zhou, X., Luo, Y., Xiao, H., Wayman, G., and Wang, H. 2011. Regulation of brain-derived neurotrophic factor exon IV transcription through calcium responsive elements in cortical neurons. PLoS One, 6(12): e28441. doi:10.1371/ ournal.pone.0028441. PMID:22174809